caprolactone has been researched along with sorafenib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, S; Chen, L; Jiang, Z; Li, A; Liang, Y; Liu, X; Ma, D; Tang, X; Zhang, Y | 1 |
| Balasubramanian, V; Fernandes, M; Hirvonen, J; Hirvonen, SP; Känkänen, V; Liu, Z; Pinto, JF; Ruokolainen, J; Santos, HA; Seitsonen, J | 1 |
2 other study(ies) available for caprolactone and sorafenib
| Article | Year |
|---|---|
Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Topics: Animals; Antibodies; Antineoplastic Agents; Caproates; Carcinoma, Hepatocellular; Cell Line, Tumor; Glypicans; Hep G2 Cells; Humans; Lactones; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Polymers; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Microfluidic preparation and optimization of sorafenib-loaded poly(ethylene glycol-block-caprolactone) nanoparticles for cancer therapy applications.
Topics: Drug Carriers; Humans; Microfluidics; Nanoparticles; Neoplasms; Particle Size; Polyesters; Polyethylene Glycols; Reproducibility of Results; Sorafenib | 2023 |